AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017
Preliminary and unaudited revenue for fourth quarter 2017 is expected to be approximately
Preliminary revenue for full year 2017 is expected to be $174.7 million, reflecting growth of approximately 13% over full year 2016. Adjusted EBITDA loss (a non-GAAP measure consistently calculated as in previous releases1) for the full year 2017 is currently estimated to be in the previously communicated range of
“Our fourth quarter results demonstrate solid financial performance as well as several accomplishments, and our business recovered nicely from the impact of the hurricanes in the third quarter. In addition, we enrolled our 100th patient in CONVERGE, surpassed the 120,000 AtriClip milestone, and launched the AtriClip PRO•V™ device as a platform for current and future growth,” said
2018 Financial Guidance
Management projects 2018 revenue of approximately
About AtriCure
Forward-Looking Statements
This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. This document also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially.
1
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005543/en/
Source:
AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer
awade@atricure.com
or
Gilmartin Group
Lynn Pieper Lewis, 415-937-5402
Investor Relations
lynn@gilmartinir.com